CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma

The use of chimeric antigen receptro T-cell therapy all over (CAR-T)-cell therapy in multiple myeloma (MM) showed early promising results in heavily pre-treated patient with limited treatment options [ [1] Berdeja J.G. Madduri D. Usmani S.Z. Jakubowiak A. Agha M. Cohen A.D. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet (London, England). 2021; 398: 314-324https://doi.org/10.1016/S0140-6736(21)00933-8 Abstract Full Text Full Text PDF PubMed Scopus (327) Google Scholar , [2] Munshi N.C. Anderson Jr., L.D. Shah N. Madduri D. Berdeja J. Lonial S. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384: 705-716https://doi.org/10.1056/NEJMoa2024850 Crossref PubMed Scopus (626) Google Scholar ]. Global use of CAR-T therapy in MM is limited. CARTIFAN-1 reported safety and efficacy data on the use of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–targeting CAR-T therapy, in relapsed/refractory multiple myeloma (RRMM) [ [3] Mi J.Q. Zhao W. Jing H. Fu W. Hu J. Chen L. et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol : official journal of the American Society of Clinical Oncology. 2022; (JCO2200690. Advance online publication)https://doi.org/10.1200/JCO.22.00690 Crossref Scopus (4) Google Scholar ]. The single-arm phase II study reported outcomes of 48 patients who received a cilta-cel infusion in China. The 18-month progression-free survival (PFS) and overall survival (OS) rates were 66.8% and 78.7%, respectively. Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myelomaEuropean Journal of CancerVol. 188PreviewDear Editor, Full-Text PDF